HUE045663T2 - Pteridinek, mint FGFR inhibitorok - Google Patents
Pteridinek, mint FGFR inhibitorokInfo
- Publication number
- HUE045663T2 HUE045663T2 HUE13731850A HUE13731850A HUE045663T2 HU E045663 T2 HUE045663 T2 HU E045663T2 HU E13731850 A HUE13731850 A HU E13731850A HU E13731850 A HUE13731850 A HU E13731850A HU E045663 T2 HUE045663 T2 HU E045663T2
- Authority
- HU
- Hungary
- Prior art keywords
- pteridines
- fgfr inhibitors
- fgfr
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003195 pteridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653081P | 2012-05-30 | 2012-05-30 | |
| GBGB1209613.7A GB201209613D0 (en) | 2012-05-30 | 2012-05-30 | New compounds |
| US201361782233P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE045663T2 true HUE045663T2 (hu) | 2020-01-28 |
Family
ID=46546195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13731850A HUE045663T2 (hu) | 2012-05-30 | 2013-05-30 | Pteridinek, mint FGFR inhibitorok |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9447098B2 (e) |
| EP (1) | EP2855480B1 (e) |
| JP (1) | JP6363068B2 (e) |
| KR (1) | KR102149759B1 (e) |
| CN (1) | CN104507944B (e) |
| AU (1) | AU2013269316C1 (e) |
| BR (1) | BR112014029709B1 (e) |
| CA (1) | CA2874967C (e) |
| DK (1) | DK2855480T3 (e) |
| ES (1) | ES2739348T3 (e) |
| GB (1) | GB201209613D0 (e) |
| HR (1) | HRP20191202T1 (e) |
| HU (1) | HUE045663T2 (e) |
| IN (1) | IN2014MN02069A (e) |
| LT (1) | LT2855480T (e) |
| MX (1) | MX359418B (e) |
| RU (1) | RU2702906C2 (e) |
| SI (1) | SI2855480T1 (e) |
| WO (1) | WO2013179033A1 (e) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| DE102013008159A1 (de) | 2012-05-14 | 2013-11-14 | Thoratec Corporation | Mantelsystem für Katheterpumpe |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| DK3122359T3 (da) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| EP3848034B1 (en) | 2014-03-26 | 2025-02-12 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| WO2015160980A1 (en) | 2014-04-15 | 2015-10-22 | Thoratec Corporation | Heart pump providing adjustable out flow |
| CN103992262B (zh) * | 2014-06-12 | 2015-11-11 | 苏州明锐医药科技有限公司 | 塞瑞替尼及其中间体的制备方法 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
| KR102691777B1 (ko) * | 2015-09-23 | 2024-08-02 | 얀센 파마슈티카 엔브이 | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 |
| MX382526B (es) | 2015-10-23 | 2025-03-13 | Array Biopharma Inc | Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr |
| IL281319B2 (en) * | 2016-04-15 | 2024-03-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors |
| JP2020517618A (ja) | 2017-04-21 | 2020-06-18 | エピザイム，インコーポレイティド | Ｅｈｍｔ２阻害剤との併用療法 |
| US11078194B2 (en) * | 2017-12-07 | 2021-08-03 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor |
| EP3745979B1 (en) | 2018-01-29 | 2025-11-19 | Bard Access Systems, Inc. | Connection system for establishing an electrical connection through a drape and methods thereof |
| EP3793464B1 (en) | 2018-05-18 | 2026-02-18 | Bard Access Systems, Inc. | Connection systems and methods thereof for establishing an electrical connection through a drape |
| US12180207B2 (en) | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP7661300B2 (ja) | 2019-07-12 | 2025-04-14 | バード・アクセス・システムズ，インコーポレーテッド | 発光ダイオードアレイを含むカテーテル追跡及び留置システム |
| WO2021026502A1 (en) | 2019-08-08 | 2021-02-11 | Bard Access Systems, Inc. | Optical-fiber connector modules including shape-sensing systems and methods thereof |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| BE1027936B1 (nl) | 2019-12-30 | 2021-08-03 | Kreco Nv | Coccolitisch krijtproduct voor toepassing in landbouw en waterbeheer |
| WO2021138392A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CR20230325A (es) | 2020-12-30 | 2023-12-11 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas |
| WO2022182972A1 (en) | 2021-02-26 | 2022-09-01 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| AU2023300357A1 (en) | 2022-06-29 | 2025-01-09 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| US20250368666A1 (en) | 2022-06-29 | 2025-12-04 | Tyra Biosciences, Inc. | Indazole compounds |
| CN114984019B (zh) * | 2022-07-15 | 2023-08-22 | 山东中医药大学 | 一种铁死亡抑制剂化合物及在肝损伤修复领域的应用 |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025129014A1 (en) | 2023-12-15 | 2025-06-19 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) * | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
| WO1994026723A2 (en) | 1993-05-14 | 1994-11-24 | Genentech, Inc. | ras FARNESYL TRANSFERASE INHIBITORS |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| WO1998054157A1 (en) | 1997-05-28 | 1998-12-03 | Rhône-Poulenc Rorer Pharmaceuticals Inc. | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| SK3542002A3 (en) * | 1999-09-15 | 2003-04-01 | Warner Lambert Co | Pteridinones as kinase inhibitors |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| JP2003013463A (ja) * | 2001-06-28 | 2003-01-15 | Works 21:Kk | マンホール施工方法 |
| WO2003051833A2 (en) | 2001-12-18 | 2003-06-26 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| EP1463506B1 (en) | 2001-12-24 | 2009-10-21 | Astrazeneca AB | Substituted quinazoline derivatives as inhibitors of aurora kinases |
| JP2003213463A (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 |
| CA2480800C (en) | 2002-04-08 | 2008-09-23 | Mark T. Bilodeau | Inhibitors of akt activity |
| US20040097725A1 (en) | 2002-07-10 | 2004-05-20 | Norman Herron | Charge transport compositions and electronic devices made with such compositions |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| CA2500727A1 (en) | 2002-10-03 | 2004-04-15 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
| WO2004098494A2 (en) | 2003-04-30 | 2004-11-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| BRPI0410348A (pt) | 2003-05-14 | 2006-05-30 | Torreypines Therapeutics Inc | compostos e usos dos mesmos na modulação de amilóide-beta |
| DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| DK1636228T3 (da) | 2003-05-23 | 2009-02-23 | Aeterna Zentaris Gmbh | Nye pyridopyraziner og deres anvendelse som kinasemodulatorer |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| AU2004259000A1 (en) | 2003-07-21 | 2005-02-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for PPAR |
| TW200517381A (en) * | 2003-08-01 | 2005-06-01 | Genelabs Tech Inc | Bicyclic heteroaryl derivatives |
| ATE369862T1 (de) | 2003-10-17 | 2007-09-15 | 4 Aza Ip Nv | Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie |
| WO2005046590A2 (en) | 2003-11-07 | 2005-05-26 | Chiron Corporation | Methods for synthesizing quinolinone compounds |
| SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| BRPI0416853A (pt) | 2003-11-24 | 2007-02-13 | Hoffmann La Roche | pirazolila e imidazolila pirimidinas |
| EP1706385B1 (en) | 2003-12-23 | 2010-10-06 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| NZ553087A (en) | 2004-08-31 | 2010-12-24 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-raf inhibitors |
| KR20080075235A (ko) | 2004-10-14 | 2008-08-14 | 에프. 호프만-라 로슈 아게 | Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논 |
| PT1830869E (pt) | 2004-12-24 | 2013-08-22 | Spinifex Pharm Pty Ltd | Método de tratamento ou profilaxia |
| AU2006212726C1 (en) | 2005-02-14 | 2013-05-16 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
| US9271963B2 (en) | 2005-03-03 | 2016-03-01 | Universitat Des Saarlandes | Selective inhibitors of human corticosteroid synthases |
| US20090156617A1 (en) | 2005-05-12 | 2009-06-18 | Northrup Alan B | Tyrosine kinase inhibitors |
| AU2006247315A1 (en) | 2005-05-18 | 2006-11-23 | Wyeth | 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| BRPI0615233A2 (pt) | 2005-08-26 | 2011-05-10 | Serono Lab | derivados de pirazina e uso dos mesmos como inibidores p13k |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| CA2628039A1 (en) | 2005-11-11 | 2007-05-18 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
| MY159523A (en) | 2005-12-21 | 2017-01-13 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| EP2024342A2 (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
| GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| ATE549338T1 (de) | 2006-05-24 | 2012-03-15 | Boehringer Ingelheim Int | Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind |
| CA2657702A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek E N Patieentenzorg | Quinazolines and related heterocyclic comp0unds, and their therapeutic use |
| JP2008127446A (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | １，５−ナフチリジン化合物及び有機発光素子 |
| CN102123712B (zh) | 2006-12-13 | 2014-03-19 | 默沙东公司 | 使用igf1r抑制剂治疗癌症的方法 |
| US7872018B2 (en) | 2006-12-21 | 2011-01-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP5442448B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物 |
| AU2007336893A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for PDK1 inhibition |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| PE20090288A1 (es) | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | Derivados de quinoxalina como inhibidores de la pi3 quinasa |
| EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| PT2172450E (pt) | 2007-06-20 | 2013-10-28 | Mitsubishi Tanabe Pharma Corp | Novo derivado sulfonamida de ácido malónico e sua utilização farmacêutica |
| EP2170894A1 (en) | 2007-06-21 | 2010-04-07 | Janssen Pharmaceutica N.V. | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
| JP2010532758A (ja) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 組み合わせ抗癌療法 |
| BRPI0814777A2 (pt) | 2007-08-08 | 2015-03-03 | Glaxosmithkline Llc | Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica. |
| WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
| JP2010535804A (ja) | 2007-08-09 | 2010-11-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体 |
| US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| KR101580482B1 (ko) | 2007-11-16 | 2015-12-28 | 인사이트 홀딩스 코포레이션 | 야누스 키나제 억제제로서의 ４－피라졸릴－ｎ－아릴피리미딘－２－아민 및 ４－피라졸릴－ｎ－헤테로아릴피리미딘－２－아민 |
| JP2011519868A (ja) | 2008-05-05 | 2011-07-14 | シェーリング コーポレイション | 癌を処置するための化学療法剤の連続投与 |
| GEP20125502B (en) | 2008-05-23 | 2012-04-25 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| US8592448B2 (en) | 2008-11-20 | 2013-11-26 | OSI Pharmaceuticals, LLC | Substituted pyrrolo[2,3-b]-pyridines and -pyrazines |
| EP2389376A1 (en) | 2009-01-21 | 2011-11-30 | Basilea Pharmaceutica AG | Novel bicyclic antibiotics |
| JP2012516847A (ja) | 2009-02-02 | 2012-07-26 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｋｔ活性の阻害剤 |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| CU24245B1 (es) | 2009-06-12 | 2017-02-02 | Centre Nat Rech Scient | QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS |
| ES2534226T3 (es) | 2009-09-03 | 2015-04-20 | Bioenergenix | Compuestos heterocíclicos para la inhibición de PASK |
| US9340528B2 (en) | 2009-09-04 | 2016-05-17 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| KR101955691B1 (ko) | 2010-03-30 | 2019-03-07 | 베르선 코포레이션 | 트롬빈 억제제로서의 다중치환된 방향족 화합물 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| CA2804304C (en) | 2010-05-24 | 2020-02-25 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102532141A (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途 |
| WO2012104776A1 (en) | 2011-01-31 | 2012-08-09 | Novartis Ag | Novel heterocyclic derivatives |
| WO2012106556A2 (en) | 2011-02-02 | 2012-08-09 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
| CN103491962B (zh) | 2011-02-23 | 2016-10-12 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| WO2013032951A1 (en) | 2011-08-26 | 2013-03-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| AU2012308238B2 (en) | 2011-09-14 | 2017-05-25 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP2757885B1 (en) | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| AU2012318580A1 (en) | 2011-10-04 | 2014-05-22 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of PI3K |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| KR20140090218A (ko) | 2011-10-28 | 2014-07-16 | 노파르티스 아게 | 신규 퓨린 유도체 및 질환의 치료에서의 그의 용도 |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| US9481911B2 (en) | 2012-03-08 | 2016-11-01 | Astellas Pharma Inc. | Methods for detecting FGFR3/TACC3 fusion genes |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| AU2014207342C1 (en) | 2013-01-18 | 2019-04-04 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| TW201536291A (zh) | 2013-08-02 | 2015-10-01 | Cephalon Inc | 單獨使用ＡＸＬ／ｃＭＥＴ抑制劑或與其它藥劑組合使用以治療多種癌症之方法 |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| EP3848034B1 (en) | 2014-03-26 | 2025-02-12 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| DK3122359T3 (da) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| JP6774421B2 (ja) | 2015-02-19 | 2020-10-21 | フュージョン ファーマシューティカルズ インク． | がんの治療のための方法、組成物、及びキット |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
-
2012
- 2012-05-30 GB GBGB1209613.7A patent/GB201209613D0/en not_active Ceased
-
2013
- 2013-05-30 MX MX2014014110A patent/MX359418B/es active IP Right Grant
- 2013-05-30 US US14/404,175 patent/US9447098B2/en active Active
- 2013-05-30 WO PCT/GB2013/051427 patent/WO2013179033A1/en not_active Ceased
- 2013-05-30 HU HUE13731850A patent/HUE045663T2/hu unknown
- 2013-05-30 BR BR112014029709-6A patent/BR112014029709B1/pt active IP Right Grant
- 2013-05-30 DK DK13731850.7T patent/DK2855480T3/da active
- 2013-05-30 CN CN201380040671.4A patent/CN104507944B/zh active Active
- 2013-05-30 IN IN2069MUN2014 patent/IN2014MN02069A/en unknown
- 2013-05-30 KR KR1020147036357A patent/KR102149759B1/ko active Active
- 2013-05-30 AU AU2013269316A patent/AU2013269316C1/en active Active
- 2013-05-30 JP JP2015514587A patent/JP6363068B2/ja active Active
- 2013-05-30 LT LTEP13731850.7T patent/LT2855480T/lt unknown
- 2013-05-30 RU RU2014153050A patent/RU2702906C2/ru active
- 2013-05-30 CA CA2874967A patent/CA2874967C/en active Active
- 2013-05-30 EP EP13731850.7A patent/EP2855480B1/en active Active
- 2013-05-30 HR HRP20191202TT patent/HRP20191202T1/hr unknown
- 2013-05-30 ES ES13731850T patent/ES2739348T3/es active Active
- 2013-05-30 SI SI201331519T patent/SI2855480T1/sl unknown
-
2016
- 2016-07-06 US US15/203,424 patent/US10272087B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014029709A2 (pt) | 2017-06-27 |
| RU2014153050A (ru) | 2016-07-20 |
| US20170000796A1 (en) | 2017-01-05 |
| US20150291589A1 (en) | 2015-10-15 |
| WO2013179033A1 (en) | 2013-12-05 |
| AU2013269316B2 (en) | 2017-10-19 |
| IN2014MN02069A (e) | 2015-08-21 |
| LT2855480T (lt) | 2019-08-12 |
| AU2013269316A1 (en) | 2014-10-30 |
| CA2874967A1 (en) | 2013-12-05 |
| EP2855480A1 (en) | 2015-04-08 |
| EP2855480B1 (en) | 2019-06-26 |
| DK2855480T3 (da) | 2019-07-22 |
| KR102149759B1 (ko) | 2020-08-31 |
| US10272087B2 (en) | 2019-04-30 |
| JP6363068B2 (ja) | 2018-07-25 |
| KR20150016595A (ko) | 2015-02-12 |
| US9447098B2 (en) | 2016-09-20 |
| MX2014014110A (es) | 2015-06-17 |
| GB201209613D0 (en) | 2012-07-11 |
| HRP20191202T1 (hr) | 2019-10-18 |
| RU2702906C2 (ru) | 2019-10-14 |
| BR112014029709B1 (pt) | 2022-03-22 |
| JP2015518039A (ja) | 2015-06-25 |
| AU2013269316C1 (en) | 2018-04-12 |
| ES2739348T3 (es) | 2020-01-30 |
| SI2855480T1 (sl) | 2019-09-30 |
| MX359418B (es) | 2018-09-27 |
| CA2874967C (en) | 2021-11-09 |
| CN104507944A (zh) | 2015-04-08 |
| CN104507944B (zh) | 2017-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289834A (en) | Conversion of tricyclic compounds as fgfr inhibitors | |
| SI2855480T1 (sl) | Pteridini kot fgfr inhibitorji | |
| ZA201407554B (en) | Dna-pk inhibitors | |
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| LT2912041T (lt) | Tetrahidropiroltiazino dariniai kaip bace slopikliai | |
| IL239153A0 (en) | Substitute pyridopyrazine as an inhibitor | |
| EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
| PL2912021T3 (pl) | Inhibitory agrekanazy |